Bluebird Bio’s Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns. Latest Ratings for BLUE Date Firm Action From To Mar 2022 Wells Fargo Maintains Equal-Weight Mar 2022 Morgan Stanley Maintains Underweight Mar 2022 Barclays Downgrades Equal-Weight Underweight View More Analyst Ratings for

U.S. election results and inflation concerns pressure renewable energy stocks. Morgan Stanley downgrades key clean tech players while backing GE Vernova and First Solar. Latest Ratings for SEDG Date Firm Action From To Mar 2022 B of A Securities Maintains Buy Feb 2022 Northland Capital Markets Maintains Underperform Feb 2022 Citigroup Maintains Buy View More

Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. read more ​  ​Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. read more 

read more ​  ​read more 

read more ​  ​read more 

read more ​  ​read more 

read more ​  ​read more 

Risk aversion dominated Wall Street in the final session of the week, driving sharp losses across major indices. read more ​  ​Risk aversion dominated Wall Street in the final session of the week, driving sharp losses across major indices. read more